



Docket No. 50875-F-PCT-US/JPW/SHS/MVM

In re application of: Graham P. Allaway et al.

RECEIVED

Serial No.: 09/460,216

JAN 11 2001

Filed: December 13, 1999

Art Unit: 1633

For: METHOD FOR PREVENTING HIV-1 INFECTION OF CD4+ CELLS

TECH CENTER 1600/2900

HONORABLE ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

January 3, 2001

S I R:

Transmitted herewith is an amendment to the above-identified application.

Small entity status of this application under 37 C.F.R. § 1.9 and § 1.27 has been established by a verified statement previously submitted.

a verified statement to establish small entity status under 37 C.F.R. § 1.9 and § 1.27 is enclosed.

No additional fee is required.

The filing fee is calculated as follows:

	NUMBER AFTER AMEND- MENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	NUMBER OF EXTRA CLAIMS PRESENTED	RATE		FEE	
				SMALL ENTITY	OTHER ENTITY	SMALL ENTITY	OTHER ENTITY
Total Claims	2	- * 20	- *** 0	x	9	18	- 0 0
Independent Claims	1	- ** 3	- *** 0	x	40	80	- 0 0
Multiple Dependent Claims(s) Presented First Time:				Yes	X No	135	270 0 0
				TOTAL ADDITIONAL \$ FEE		0	

If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.

* If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.

*** If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than "0", write "0" in the space.

Applicant: Graham P. Allaway et al.
Serial No.: 09/460,216
Filed: December 13, 1999

RECEIVED

JAN 11 2001

Amendment Transmittal Letter
Page 2

TECH CENTER 1600/2000

The "HIGHEST NUMBER PREVIOUSLY PAID FOR" (Total or Independent) is the highest of the "NUMBER AFTER AMENDMENT" in any prior amendment or the number of claims as originally filed.

Please charge Deposit Account No. _____
in the amount of \$ _____.

A check in the amount of \$ _____ is enclosed.


The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 03-3125. Three copies of this sheet are enclosed.

Any filing fees under 37 C.F.R. §1.16 for the presentation of extra claims.

Any patent application processing fees under 37 C.F.R. §1.17.

Respectfully submitted,


John P. White
Registration No. 28,678
Spencer H. Schneider
Registration No. 45,923
Attorneys for Applicant(s)
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.	
	1-3-01
John P. White	Date
Reg. No. 28,678	
Spencer H. Schneider	
Reg. No. 45,923	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Graham P. Allaway, et al.

Serial No.: 09/460,216

Filed : December 13, 1999 Art Unit: 1633

For METHOD FOR PREVENTING HIV-1 INFECTION OF CD4+ CELLS



1185 Avenue of the Americas
New York, New York 10036
January 3, 2001

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

SECOND PRELIMINARY AMENDMENT

Please amend the subject application as follows:

In the claims:

Please cancel claims 62-64 without prejudice or disclaimer to applicants' right to pursue the subject matter of these claims in a later-filed application. Please also amend claim 61 under the provisions of 37 C.F.R. § 1.121(a)(2) by deleting the bracketed material and inserting the underlined material and add new claim 65 as follows.

13
--61. (2X Amended) A method of inhibiting HIV-1 infection of a CD4+ cell[s] which comprises contacting the CD4+ cell[s] with a [non-chemokine peptidyl] nonpeptidyl agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-1 or an HIV-1 infected cell to the CD4+ cell[s] is inhibited, so as to thereby inhibit HIV-1 infection of the CD4+ cell[s], provided that the [nonchemokine peptidyl] nonpeptidyl agent is not a bicyclam or a derivative thereof.--

13
--65. (New) The method of claim 61, wherein the chemokine receptor is a CCR5 chemokine receptor.--